Stránka klinických studií Nct

Summary
EudraCT Number:2009-017319-13
Sponsor's Protocol Code Number:C-09-033
National Competent Authority:Finland - Fimea
Clinical Trial Type:EEA CTA
Trial Status:Prematurely Ended
Date on which this record was first entered in the EudraCT database:2010-12-02
Trial results View results
Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL
A. Protocol Information
A.1Member State ConcernedFinland - Fimea
A.2EudraCT number2009-017319-13
A.3Full title of the trial
Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes
A.3.2Name or abbreviated title of the trial where available
Safety and Efficacy of Moxidex Otic Solution in AOMT
A.4.1Sponsor's protocol code numberC-09-033
A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorAlcon Research Ltd.
B.1.3.4CountryUnited States
B.3.1 and B.3.2Status of the sponsorCommercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing support
B.4.2Country
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisation
B.5.2Functional name of contact point
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namemoxifloxacin 0.5% and dexamethasone sodium phosphate 0.1% (Moxidex)
D.3.2Product code AL-15469A
D.3.4Pharmaceutical form Ear drops, solution
D.3.4.1Specific paediatric formulation Information not present in EudraCT
D.3.7Routes of administration for this IMPAuricular use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNMOXIFLOXACIN HYDROCHLORIDE
D.3.9.1CAS number 186826868
D.3.9.2Current sponsor codeAL-15469A
D.3.9.3Other descriptive nameMOXIFLOXACIN
D.3.10 Strength
D.3.10.1Concentration unit % percent
D.3.10.2Concentration typeequal
D.3.10.3Concentration number0.5
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNDEXAMETHASONE SODIUM PHOSPHATE
D.3.9.1CAS number 2392-39-4
D.3.9.2Current sponsor codeAL-38905
D.3.9.3Other descriptive nameDEXAMETHASONE
D.3.10 Strength
D.3.10.1Concentration unit % percent
D.3.10.2Concentration typeequal
D.3.10.3Concentration number0.1
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin Yes
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Information not present in EudraCT
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.IMP: 2
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namemoxifloxacin
D.3.2Product code AL-38905
D.3.4Pharmaceutical form Ear drops, solution
D.3.4.1Specific paediatric formulation Information not present in EudraCT
D.3.7Routes of administration for this IMPAuricular use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNMOXIFLOXACIN HYDROCHLORIDE
D.3.9.1CAS number 186826868
D.3.9.2Current sponsor codeAL-15469A
D.3.9.3Other descriptive nameMOXIFLOXACIN
D.3.10 Strength
D.3.10.1Concentration unit % percent
D.3.10.2Concentration typeequal
D.3.10.3Concentration number0.5
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin Yes
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Information not present in EudraCT
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
D.8 Placebo: 1
D.8.1Is a Placebo used in this Trial?Yes
D.8.3Pharmaceutical form of the placeboEar drops, solution
D.8.4Route of administration of the placeboAuricular use
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Acute otitis media with otorrhea in tympanostomy tubes
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2Version 12.1
E.1.2Level LLT
E.1.2Classification code 10033079
E.1.2Term Otitis media acute
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
To evaluate the safety and efficacy of topical Moxidex for the treatment of patients with acute otitis media with tympanostomy tubes (AOMT);

To demonstrate the therapeutic superiority of Moxidex relative to Moxifloxacin based on clinical cures at end of treatment (EOT);

To demonstrate therapeutic superiority of Moxifloxacin relative to Vehicle based on clinical cures at EOT.
E.2.2Secondary objectives of the trial
E.2.3Trial contains a sub-study No
E.3Principal inclusion criteria
1) At least 6 months and no more than 12 years of age at the time of enrollment
2) Presence of otorrhea at Visit 1 of 21 days or less in duration, visible by the parent/guardian in at least 1 ear
3) Presence of patent tympanostomy tube(s). Patients with obstructed tympanostomy tube(s) that cannot be cleared at the time of enrollment MUST NOT be enrolled
4) Will refrain from significant water immersion of the ear(s) without the use of adequate ear protection during swimming, bathing, showering, and other water-related activities
5) Read and signed (by parent or guardian) the informed consent. When required by the Institutional Review Board, the child must agree to sign an approved assent form
6) Patient and parent/guardian mut agree to comply with the requirements of the study. Parent/guardian must agree to administer the study medication as directed, complete the required study visits, accurately complete twice daily phone calls into the IVRS system, and participate in 5 compliance phone contacts
E.4Principal exclusion criteria
1) Patients who have NOT been otorrhea-free for at least seven (7) days following tympanostomy tube surgery
2) Tympanostomy tubes containing antimicrobial agents or any tube longer than 2.5 mm that my prohibit verification of tube patency
3) History of/or current acute or chronic non-tube otorrhea (through existing perforation of the eardrum)
4) Current acute otitis externa (AOE), or malignant otitis externa (MOE) or other conditions which could interfere with evaluatio nof the study drug
5) Known or suspected ear infection of fungal or mycobacterial origin
6) History of/or active herpes simplex, vacinna or varicella infections or overt viral infections of the tympanic membrane (eg, myringitis bullosa) or ear canal. Patients with a history of/or active herpetic infections in locations other than the ear may be enrolled
7) Prior otologic surgery, except those confined to the tympanic membrane, within 1 year or study entry
8) Mastoiditis or other suppurative noninfectious disorders in the ear(s)
E.5 End points
E.5.1Primary end point(s)
Clinical cure rate at the Day 8 (EOT) visit. Clinical cure is attained if the clinical response is resolved/cured (ie, absence of otorrhea) as evaluated by the Investigator (ie, Clinical Response) at the EOT visit.
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis No
E.6.3Therapy No
E.6.4Safety Yes
E.6.5Efficacy Yes
E.6.6Pharmacokinetic No
E.6.7Pharmacodynamic No
E.6.8Bioequivalence No
E.6.9Dose response No
E.6.10Pharmacogenetic No
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others No
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) No
E.7.3Therapeutic confirmatory (Phase III) Yes
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled Yes
E.8.1.1Randomised Yes
E.8.1.2Open No
E.8.1.3Single blind No
E.8.1.4Double blind Yes
E.8.1.5Parallel group Yes
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) Yes
E.8.2.2Placebo Yes
E.8.2.3Other No
E.8.3 The trial involves single site in the Member State concerned No
E.8.4 The trial involves multiple sites in the Member State concerned Yes
E.8.4.1Number of sites anticipated in Member State concerned4
E.8.5The trial involves multiple Member States Yes
E.8.5.1Number of sites anticipated in the EEA15
E.8.6 Trial involving sites outside the EEA
E.8.6.1Trial being conducted both within and outside the EEA Yes
E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
E.8.7Trial has a data monitoring committee No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
E.8.9 Initial estimate of the duration of the trial
E.8.9.1In the Member State concerned years1
E.8.9.1In the Member State concerned months0
E.8.9.1In the Member State concerned days0
E.8.9.2In all countries concerned by the trial years1
E.8.9.2In all countries concerned by the trial months0
E.8.9.2In all countries concerned by the trial days0
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 Yes
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) Yes
F.1.1.5Children (2-11years) Yes
F.1.1.6Adolescents (12-17 years) Yes
F.1.2Adults (18-64 years) No
F.1.3Elderly (>=65 years) No
F.2 Gender
F.2.1Female Yes
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers No
F.3.2Patients Yes
F.3.3Specific vulnerable populations Yes
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception No
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally Yes
F.3.3.6.1Details of subjects incapable of giving consent
Children 6 months to 12 years will be enrolled. Assent is required per ethics committee requirement.
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.1In the member state75
F.4.2 For a multinational trial
F.4.2.2In the whole clinical trial 1300
G. Investigator Networks to be involved in the Trial
N. Review by the Competent Authority or Ethics Committee in the country concerned
N.Competent Authority Decision Authorised
N.Date of Competent Authority Decision2011-02-14
N.Ethics Committee Opinion of the trial applicationFavourable
N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.Date of Ethics Committee Opinion2011-01-04
P. End of Trial
P.End of Trial StatusPrematurely Ended
P.Date of the global end of the trial2011-10-14

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit